Translational Genomics Research Institute
Latest From Translational Genomics Research Institute
FDA’s decision to seek the withdrawal of Ariad’s Iclusig prompted concerns about greater caution by the agency in the “Breakthrough” era. A more important implication, however, may be in whether the continued access program succeeds in meeting demand for the product. That could become a model for future development of ever-more personalized cancer treatment regimens.
Forma Therapeutics has already convinced several big industry partners its discovery engine will yield oncology candidates in emerging areas of research. Now it wants to find academic groups to help feed its engine, all while the resurgent biotech IPO market might make its unusual structure superfluous.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.